Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 1;4(3):1.
doi: 10.1167/tvst.4.3.1. eCollection 2015 May.

Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery

Kishore Cholkar, Brian C Gilger, Ashim K Mitra

Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery

Kishore Cholkar et al. Transl Vis Sci Technol. .

Abstract

Purpose: The main objective of this study was to optimize cyclosporine (CsA) nanomicellar solution and study in vivo ocular CsA tissue distribution with a topical drop.

Methods: An optimized blend of hydrogenated castor oil-40 and octoxynol-40 was prepared to entrap CsA within nanomicelles. In vivo studies were conducted in New Zealand White albino rabbits with topical drop instillation.

Results: Average size of CsA-loaded nanomicelles was approximately 22.4 nm. Ocular tissue CsA quantification with single and multiple dosing revealed that CsA levels followed as cornea → iris-ciliary body → aqueous humor → lens. Cyclosporine levels were also found to be in the following order: conjunctiva → sclera → retina/choroid → vitreous humor. High CsA level was detected in retina/choroid (53.7 ng/g tissue).

Conclusions: Ocular tissue CsA distribution studies revealed high CsA concentrations in anterior ocular tissues. Moreover, it appears that nanomicelles are transported through a conjunctival-scleral pathway and deliver CsA to the retina/choroid. Results suggest polymeric blend to be a safe carrier for anterior and posterior ocular tissues.

Translational relevance: This study has significant translational relevance, disclosing results that suggest that aqueous nanomicellar approach can provide high corneal and conjunctival CsA concentrations. Aqueous nanomicelles can deliver high drug concentrations not only to anterior but also to back of the eye tissues, including retina. This article provides a platform for noninvasive back of the eye drug delivery with topical eye drops. Aqueous CsA nanomicelles have no perceptible toxicity such as cell membrane damage or cytotoxicity to corneal and retinal pigment epithelial cells. Clear aqueous nanomicellar solution can be translated to human conditions for keratoconjunctivitis sicca and other anti-inflammatory conditions.

Keywords: back of the eye; cyclosporine; drops; drug delivery; dry eye; formulation; nanomicelles; posterior; rabbits; retina/choroid; sclera; topical.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histogram showing size distribution for NMF. (A) Size distribution for placebo NMF. (B) Size distribution for 0.1% CsA NMF.
Figure 2
Figure 2
(A) Picture showing 0.1% CsA-loaded NMF (right) in comparison to water (left). (B) TEM image for 0.1% CsA-loaded NMF (scale: 500 nm).
Figure 3
Figure 3
(A) 1H NMR for CsA in CDCl3. (B) 1H NMR spectra for placebo or blank nanomicelles. (C) 1H NMR for CsA-loaded nanomicelles suspended in CDCl3 (*CsA resonance peaks are evident). (D) 1H NMR for CsA-loaded nanomicelles suspended in D2O (no resonance peaks are observed/identified for cyclosporine).
Figure 4
Figure 4
(A) Cell proliferation assay for rPCEC and D407 cells incubated with NMF (placebo and cyclosporine-A [CsA] loaded) for a period of 1 hour. Values represent mean ± SD (n = 4). *P < 0.05 is statistically significant. (B) LDH assay results for placebo and CsA-loaded NMF for a period of 2 hours. Values represent mean ± SD (n = 4). *P < 0.05 is statistically significant.
Figure 5
Figure 5
(A) CsA-loaded nanomicelles composed of HCO-40 and Oc-40. (B) Partial reversal of CsA-loaded nanomicelles. (C) Complete reversal of nanomicelles and CsA release upon contacting lipoidal ocular tissues.
See this image and copyright information in PMC

References

    1. Mondon K,, Zeisser-Labouebe M, Gurny R,, et al. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study. Eur J Pharm Biopharm. 2011; 77: 56–65. - PubMed
    1. Matsuda S, Koyasu S.Mechanisms of action of cyclosporine. Immunopharmacology. 2000; 47: 119–125. - PubMed
    1. Whitcup SM, Chan CC,, Luyo DA, et al. Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest Ophthalmol Vis Sci. 1996; 37: 2686–2693. - PubMed
    1. Kunert KS,, Tisdale AS, Gipson IK.Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120: 330–337. - PubMed
    1. Gunduz K, Ozdemir O.Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh). 1994; 72: 438–442. - PubMed